Tuberculosis vaccine development: Shifting focus amid increasing development challenges

References

• Oettinger T, Jorgensen M, Ladefoged A, Haslov K, Andersen P. Development of the Mycobacterium bovis BCG vaccine: review of the historical and biochemical evidence for a genealogical tree. Tuber Lung Dis 1999; 79:243-50; PMID:10692993; http://dx.doi.org/10.1054/tuld.1999.0206
   PubMedGoogle Scholar
• Zwerling A, Behr MA, Verma A, Brewer TF, Menzies D, Pai M. The BCG World Atlas: a database of global BCG vaccination policies and practices. PLoS Med 2011; 8:e1001012; PMID:21445325; http://dx.doi.org/10.1371/journal.pmed.1001012
   PubMed Web of Science ®Google Scholar
• Rodrigues LC, Diwan VK, Wheeler JG. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol 1993; 22:1154-8; PMID:8144299; http://dx.doi.org/10.1093/ije/22.6.1154
   PubMed Web of Science ®Google Scholar
• Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006; 367:1173-80; PMID:16616560; http://dx.doi.org/10.1016/S0140-6736(06)68507-3
   PubMed Web of Science ®Google Scholar
• Andersen P, Doherty TM. The success and failure of BCG - implications for a novel tuberculosis vaccine. Nat Rev Microbiol 2005; 3:656-62; PMID:16012514; http://dx.doi.org/10.1038/nrmicro1211
   PubMed Web of Science ®Google Scholar
• Brandt L, Feino Cunha J, Weinreich Olsen A, Chilima B, Hirsch P, Appelberg R, Andersen P. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect Immun 2002; 70:672-8; PMID:11796598; http://dx.doi.org/10.1128/IAI.70.2.672-678.2002
   PubMed Web of Science ®Google Scholar
• Hokey DA, Ginsberg A. The current state of tuberculosis vaccines. Human vaccines & immunotherapeutics 2013; 9:2142-6; PMID:23792698; http://dx.doi.org/10.4161/hv.25427
   PubMed Web of Science ®Google Scholar
• Moss WJ, Clements CJ, Halsey NA. Immunization of children at risk of infection with human immunodeficiency virus. Bull World Health Organ 2003; 81:61-70; PMID:12640478
   PubMed Web of Science ®Google Scholar
• Talbot EA, Perkins MD, Silva SF, Frothingham R. Disseminated bacille Calmette-Guerin disease after vaccination: case report and review. Clin Infect Dis 1997; 24:1139-46; PMID:9195072; http://dx.doi.org/10.1086/513642
   PubMed Web of Science ®Google Scholar
• Malin AS, McAdam KP. Escalating threat from tuberculosis: the third epidemic. Thorax 1995; 50 Suppl 1:S37-42; http://dx.doi.org/10.1136/thx.50.Suppl_1.S37
   Google Scholar
• Falzon D, Jaramillo E, Schunemann HJ, Arentz M, Bauer M, Bayona J, Blanc L, Caminero JA, Daley CL, Duncombe C, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38:516-28; http://dx.doi.org/10.1183/09031936.00073611
   PubMed Web of Science ®Google Scholar
• Zignol M, van Gemert W, Falzon D, Sismanidis C, Glaziou P, Floyd K, Raviglione M. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007–2010. Bull World Health Organ 2012; 90:111-9D; PMID:22423162; http://dx.doi.org/10.2471/BLT.11.092585
   PubMed Web of Science ®Google Scholar
• WHO declares TB an emergency in Africa. Indian J Med Sci 2005; 59:367-8; PMID:16231441
   PubMedGoogle Scholar
• Global. WHO declares emergency against AIDS, TB, malaria. AIDS Policy Law 2006; 21:5
   Google Scholar
• Global Tuberculosis Report 2014. Geneva, Switzerland: World Health Organization, 2014.
   Google Scholar
• Global Tuberculosis Report 2010. Geneva, Switzerland: World Health Organization, 2010.
   Google Scholar
• Global Tuberculosis Report 2011. Geneva, Switzerland: World Health Organization, 2011.
   Google Scholar
• Global Tuberculosis Report 2012. Geneva, Switzerland: World Health Organization, 2012.
   Google Scholar
• Global Tuberculosis Report 2013. Geneva, Switzerland: World Health Organization, 2013.
   Google Scholar
• Tufariello JM, Chan J, Flynn JL. Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection. Lancet Infect Dis 2003; 3:578-90; PMID:12954564; http://dx.doi.org/10.1016/S1473-3099(03)00741-2
   PubMed Web of Science ®Google Scholar
• Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C. Totally drug-resistant tuberculosis in India. Clin Infect Dis 2012; 54:579-81; PMID:22190562; http://dx.doi.org/10.1093/cid/cir889
   PubMed Web of Science ®Google Scholar
• Velayati AA, Farnia P, Masjedi MR, Ibrahim TA, Tabarsi P, Haroun RZ, Kuan HO, Ghanavi J, Varahram M. Totally drug-resistant tuberculosis strains: evidence of adaptation at the cellular level. Eur Respir J 2009; 34:1202-3; http://dx.doi.org/10.1183/09031936.00081909
   PubMed Web of Science ®Google Scholar
• Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, Ziazarifi AH, Hoffner SE. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran. Chest 2009; 136:420-5; PMID:19349380; http://dx.doi.org/10.1378/chest.08-2427
   PubMed Web of Science ®Google Scholar
• Altare F, Durandy A, Lammas D, Emile JF, Lamhamedi S, Le Deist F, Drysdale P, Jouanguy E, Doffinger R, Bernaudin F, et al. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 1998; 280:1432-5; PMID:9603732; http://dx.doi.org/10.1126/science.280.5368.1432
   PubMed Web of Science ®Google Scholar
• Chaisson RE, Martinson NA. Tuberculosis in Africa–combating an HIV-driven crisis. N Engl J Med 2008; 358:1089-92; PMID:18337598; http://dx.doi.org/10.1056/NEJMp0800809
   PubMed Web of Science ®Google Scholar
• Chen CY, Huang D, Wang RC, Shen L, Zeng G, Yao S, Shen Y, Halliday L, Fortman J, McAllister M, et al. A critical role for CD8 T cells in a nonhuman primate model of tuberculosis. PLoS pathogens 2009; 5:e1000392; PMID:19381260; http://dx.doi.org/10.1371/journal.ppat.1000392
   PubMed Web of Science ®Google Scholar
• de Jong R, Altare F, Haagen IA, Elferink DG, Boer T, van Breda Vriesman PJ, Kabel PJ, Draaisma JM, van Dissel JT, Kroon FP, et al. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science 1998; 280:1435-8; PMID:9603733; http://dx.doi.org/10.1126/science.280.5368.1435
   PubMed Web of Science ®Google Scholar
• Flynn JL, Goldstein MM, Triebold KJ, Koller B, Bloom BR. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc Natl Acad Sci U S A 1992; 89:12013-7; PMID:1465432; http://dx.doi.org/10.1073/pnas.89.24.12013
   PubMed Web of Science ®Google Scholar
• Jouanguy E, Doffinger R, Dupuis S, Pallier A, Altare F, Casanova JL. IL-12 and IFN-gamma in host defense against mycobacteria and salmonella in mice and men. Curr Opin Immunol 1999; 11:346-51; PMID:10375558; http://dx.doi.org/10.1016/S0952-7915(99)80055-7
   PubMed Web of Science ®Google Scholar
• Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345:1098-104; PMID:11596589; http://dx.doi.org/10.1056/NEJMoa011110
   PubMed Web of Science ®Google Scholar
• Lammas DA, Casanova JL, Kumararatne DS. Clinical consequences of defects in the IL-12-dependent interferon-gamma (IFN-gamma) pathway. Clin Exp Immunol 2000; 121:417-25; PMID:10971505; http://dx.doi.org/10.1046/j.1365-2249.2000.01284.x
   PubMed Web of Science ®Google Scholar
• Nunez Martinez O, Ripoll Noiseux C, Carneros Martin JA, Gonzalez Lara V, Gregorio Maranon HG. Reactivation tuberculosis in a patient with anti-TNF-alpha treatment. Am J Gastroenterol 2001; 96:1665-6; PMID:11374737
   PubMed Web of Science ®Google Scholar
• Pacheco AG, Durovni B, Cavalcante SC, Lauria LM, Moore RD, Moulton LH, Chaisson RE, Golub JE. AIDS-related tuberculosis in Rio de Janeiro, Brazil. PLoS One 2008; 3:e3132; PMID:18781195; http://dx.doi.org/10.1371/journal.pone.0003132
   PubMedGoogle Scholar
• Pawlowski A, Jansson M, Skold M, Rottenberg ME, Kallenius G. Tuberculosis and HIV co-infection. PLoS pathogens 2012; 8:e1002464; PMID:22363214; http://dx.doi.org/10.1371/journal.ppat.1002464
   PubMed Web of Science ®Google Scholar
• Wangoo A, Sparer T, Brown IN, Snewin VA, Janssen R, Thole J, Cook HT, Shaw RJ, Young DB. Contribution of Th1 and Th2 cells to protection and pathology in experimental models of granulomatous lung disease. J Immunol 2001; 166:3432-9; PMID:11207301; http://dx.doi.org/10.4049/jimmunol.166.5.3432
   PubMed Web of Science ®Google Scholar
• Graves A, Hokey D. Tuberculosis vaccines: review of current development trends and future challenges. J Bioterr Biodef 2011:009
   Google Scholar
• McShane H, Pathan AA, Sander CR, Goonetilleke NP, Fletcher HA, Hill AV. Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis (Edinburgh, Scotland) 2005; 85:47-52; PMID:15687027; http://dx.doi.org/10.1016/j.tube.2004.09.015
   PubMed Web of Science ®Google Scholar
• Beveridge NE, Price DA, Casazza JP, Pathan AA, Sander CR, Asher TE, Ambrozak DR, Precopio ML, Scheinberg P, Alder NC, et al. Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur J Immunol 2007; 37:3089-100; PMID:17948267; http://dx.doi.org/10.1002/eji.200737504
   PubMed Web of Science ®Google Scholar
• Hawkridge T, Scriba TJ, Gelderbloem S, Smit E, Tameris M, Moyo S, Lang T, Veldsman A, Hatherill M, Merwe L, et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J Infect Dis 2008; 198:544-52; PMID:18582195; http://dx.doi.org/10.1086/590185
   PubMed Web of Science ®Google Scholar
• Vordermeier HM, Rhodes SG, Dean G, Goonetilleke N, Huygen K, Hill AV, Hewinson RG, Gilbert SC. Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guerin. Immunology 2004; 112:461-70; PMID:15196215; http://dx.doi.org/10.1111/j.1365-2567.2004.01903.x
   PubMed Web of Science ®Google Scholar
• Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, Shea JE, McClain JB, Hussey GD, Hanekom WA, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013; 381:1021-8; PMID:23391465; http://dx.doi.org/10.1016/S0140-6736(13)60177-4
   PubMed Web of Science ®Google Scholar
• Ndiaye BP, Thienemann F, Ota M, Landry BS, Camara M, Dieye S, Dieye TN, Esmail H, Goliath R, Huygen K, et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial. Lancet Respir Med 2015; 3(3):190-200; PMID:25726088
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Phase I Trial of DAR-901. National Institutes of Health, 2015.
   Google Scholar
• da Costa AC, Costa-Junior Ade O, de Oliveira FM, Nogueira SV, Rosa JD, Resende DP, Kipnis A, Junqueira-Kipnis AP. A new recombinant BCG vaccine induces specific Th17 and Th1 effector cells with higher protective efficacy against tuberculosis. PLoS One 2014; 9:e112848; PMID:25398087; http://dx.doi.org/10.1371/journal.pone.0112848
   PubMed Web of Science ®Google Scholar
• Doz E, Lombard R, Carreras F, Buzoni-Gatel D, Winter N. Mycobacteria-infected dendritic cells attract neutrophils that produce IL-10 and specifically shut down Th17 CD4 T cells through their IL-10 receptor. J Immunol 2013; 191:3818-26; PMID:23997221; http://dx.doi.org/10.4049/jimmunol.1300527
   PubMed Web of Science ®Google Scholar
• Verwaerde C, Debrie AS, Dombu C, Legrand D, Raze D, Lecher S, Betbeder D, Locht C. HBHA vaccination may require both Th1 and Th17 immune responses to protect mice against tuberculosis. Vaccine 2014; 32:6240-50; PMID:25252198; http://dx.doi.org/10.1016/j.vaccine.2014.09.024
   PubMed Web of Science ®Google Scholar
• Dhiman R, Venkatasubramanian S, Paidipally P, Barnes PF, Tvinnereim A, Vankayalapati R. Interleukin 22 inhibits intracellular growth of Mycobacterium tuberculosis by enhancing calgranulin A expression. J Infect Dis 2014; 209:578-87; PMID:24041785; http://dx.doi.org/10.1093/infdis/jit495
   PubMed Web of Science ®Google Scholar
• Gold MC, Napier RJ, Lewinsohn DM. MR1-restricted mucosal associated invariant T (MAIT) cells in the immune response to Mycobacterium tuberculosis. Immunol Rev 2015; 264:154-66; PMID:25703558; http://dx.doi.org/10.1111/imr.12271
   PubMed Web of Science ®Google Scholar
• Sharma PK, Wong EB, Napier RJ, Bishai WR, Ndung'u T, Kasprowicz VO, Lewinsohn DA, Lewinsohn DM, Gold MC. High Expression of CD26 Accurately Identifies Human Bacterial-Reactive MR1-restricted MAIT cells. Immunology 2015; 145(3):84-7 PMID:25752900
   PubMed Web of Science ®Google Scholar
• Saitoh T, Yano I, Kumazawa Y, Takimoto H. Pulmonary TCR gammadelta T cells induce the early inflammation of granuloma formation by a glycolipid trehalose 6,6′-dimycolate (TDM) isolated from Mycobacterium tuberculosis. Immunopharmacol Immunotoxicol 2012; 34:815-23; PMID:22963130; http://dx.doi.org/10.3109/08923973.2012.658922
   PubMed Web of Science ®Google Scholar
• Flingai S, Czerwonko M, Goodman J, Kudchodkar SB, Muthumani K, Weiner DB. Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants. Front Immunol 2013; 4:354; PMID:24204366; http://dx.doi.org/10.3389/fimmu.2013.00354
   PubMed Web of Science ®Google Scholar
• Achkar JM, Chan J, Casadevall A. Role of B Cells and Antibodies in Acquired Immunity against Mycobacterium tuberculosis. Cold Spring Harb Perspect Med 2014; 5:a018432 PMID:25301934
   PubMedGoogle Scholar
• Orme IM. Vaccines to prevent tuberculosis infection rather than disease: Physiological and immunological aspects. Tuberculosis (Edinburgh, Scotland) 2014.
   Google Scholar
• Kleinnijenhuis J, Quintin J, Preijers F, Joosten LA, Jacobs C, Xavier RJ, van der Meer JW, van Crevel R, Netea MG. BCG-induced trained immunity in NK cells: Role for non-specific protection to infection. Clin Immunol 2014; 155:213-9; PMID:25451159; http://dx.doi.org/10.1016/j.clim.2014.10.005
   PubMed Web of Science ®Google Scholar
• Ottenhoff TH. New pathways of protective and pathological host defense to mycobacteria. Trends Microbiol 2012; 20:419-28; PMID:22784857; http://dx.doi.org/10.1016/j.tim.2012.06.002
   PubMed Web of Science ®Google Scholar
• Zambrano-Zaragoza JF, Romo-Martinez EJ, Duran-Avelar Mde J, Garcia-Magallanes N, Vibanco-Perez N. Th17 cells in autoimmune and infectious diseases. Int J Inflam 2014; 2014:651503; PMID:25152827; http://dx.doi.org/10.1155/2014/651503
   PubMedGoogle Scholar
• Van Rhijn I, Moody DB. CD1 and mycobacterial lipids activate human T cells. Immunol Rev 2015; 264:138-53; PMID:25703557; http://dx.doi.org/10.1111/imr.12253
   PubMed Web of Science ®Google Scholar
• Darrah PA, Bolton DL, Lackner AA, Kaushal D, Aye PP, Mehra S, Blanchard JL, Didier PJ, Roy CJ, Rao SS, et al. Aerosol vaccination with AERAS-402 elicits robust cellular immune responses in the lungs of rhesus macaques but fails to protect against high-dose Mycobacterium tuberculosis challenge. J Immunol 2014; 193:1799-811; PMID:25024382; http://dx.doi.org/10.4049/jimmunol.1400676
   PubMed Web of Science ®Google Scholar
• Hokey DA, Wachholder R, Darrah PA, Bolton DL, Barouch DH, Hill K, Dheenadhayalan V, Schwander S, Godin CS, Douoguih M, et al. A nonhuman primate toxicology and immunogenicity study evaluating aerosol delivery of AERAS-402/Ad35 vaccine: Evidence for transient t cell responses in peripheral blood and robust sustained responses in the lungs. Human Vaccin Immunother 2014; 10:2199-210; PMID:25424923; http://dx.doi.org/10.4161/hv.29108
   PubMed Web of Science ®Google Scholar
• Satti I, Meyer J, Harris SA, Manjaly Thomas ZR, Griffiths K, Antrobus RD, Rowland R, Ramon RL, Smith M, Sheehan S, et al. Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial. Lancet Infect Dis 2014; 14:939-46; PMID:25151225; http://dx.doi.org/10.1016/S1473-3099(14)70845-X
   PubMed Web of Science ®Google Scholar
• Graves AJ, Padilla MG, Hokey DA. OMIP-022: Comprehensive assessment of antigen-specific human T-cell functionality and memory. Cytometry A 2014; 85:576-9; PMID:24866990; http://dx.doi.org/10.1002/cyto.a.22478
   PubMed Web of Science ®Google Scholar
• Sutherland JS, Loxton AG, Haks MC, Kassa D, Ambrose L, Lee JS, Ran L, van Baarle D, Maertzdorf J, Howe R, et al. Differential gene expression of activating Fcgamma receptor classifies active tuberculosis regardless of human immunodeficiency virus status or ethnicity. Clin Microbiol Infect 2014; 20:O230-8; PMID:24205913; http://dx.doi.org/10.1111/1469-0691.12383
   PubMed Web of Science ®Google Scholar
• Matsumiya M, Harris SA, Satti I, Stockdale L, Tanner R, O'Shea MK, Tameris M, Mahomed H, Hatherill M, Scriba TJ, et al. Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response. BMC Infect Dis 2014; 14:314; PMID:24912498; http://dx.doi.org/10.1186/1471-2334-14-314
   PubMed Web of Science ®Google Scholar
• Orme IM, Basaraba RJ. The formation of the granuloma in tuberculosis infection. Semin Immunol 2014; 26:601-9; PMID:25453231; http://dx.doi.org/10.1016/j.smim.2014.09.009
   PubMed Web of Science ®Google Scholar
• Niemann S, Supply P. Diversity and evolution of Mycobacterium tuberculosis: moving to whole-genome-based approaches. Cold Spring Harb Perspect Med 2014; 4:a021188; PMID:25190252; http://dx.doi.org/10.1101/cshperspect.a021188
   PubMed Web of Science ®Google Scholar
• McShane H, Williams A. A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data. Tuberculosis (Edinburgh, Scotland) 2014; 94:105-10; PMID:24369986; http://dx.doi.org/10.1016/j.tube.2013.11.003
   PubMed Web of Science ®Google Scholar
• Flynn JL, Gideon HP, Mattila JT, Lin PL. Immunology studies in non-human primate models of tuberculosis. Immunol Rev 2015; 264:60-73; PMID:25703552; http://dx.doi.org/10.1111/imr.12258
   PubMed Web of Science ®Google Scholar
• Shi C, Shi J, Xu Z. A review of murine models of latent tuberculosis infection. Scand J Infect Dis 2011; 43:848-56; PMID:21892898; http://dx.doi.org/10.3109/00365548.2011.603745
   PubMed Web of Science ®Google Scholar
• Zelmer A, Carroll P, Andreu N, Hagens K, Mahlo J, Redinger N, Robertson BD, Wiles S, Ward TH, Parish T, et al. A new in vivo model to test anti-tuberculosis drugs using fluorescence imaging. J Antimicrob Chemother 2012; 67:1948-60; PMID:22635525; http://dx.doi.org/10.1093/jac/dks161
   PubMed Web of Science ®Google Scholar
• Hokey DA. TB Vaccines: The (Human) Challenge Ahead. Mycobact Dis 2014; 4:e128; http://dx.doi.org/10.4172/2161-1068.1000e128
   PubMedGoogle Scholar
• Duncan CJ, Draper SJ. Controlled human blood stage malaria infection: current status and potential applications. Am J Trop Med Hyg 2012; 86:561-5; PMID:22492136; http://dx.doi.org/10.4269/ajtmh.2012.11-0504
   PubMed Web of Science ®Google Scholar
• Sedegah M, Hollingdale MR, Farooq F, Ganeshan H, Belmonte M, Kim Y, Peters B, Sette A, Huang J, McGrath S, et al. Sterile immunity to malaria after DNA prime/adenovirus boost immunization is associated with effector memory CD8+T cells targeting AMA1 class I epitopes. PLoS One 2014; 9:e106241; PMID:25211344; http://dx.doi.org/10.1371/journal.pone.0106241
   PubMed Web of Science ®Google Scholar
• Seder RA, Chang LJ, Enama ME, Zephir KL, Sarwar UN, Gordon IJ, Holman LA, James ER, Billingsley PF, Gunasekera A, et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 2013; 341:1359-65; PMID:23929949; http://dx.doi.org/10.1126/science.1241800
   PubMed Web of Science ®Google Scholar
• Harris SA, Meyer J, Satti I, Marsay L, Poulton ID, Tanner R, Minassian AM, Fletcher HA, McShane H. Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate tuberculosis vaccine, MVA85A, alone and in combination. J Infect Dis 2014; 209:1259-68; PMID:24273174; http://dx.doi.org/10.1093/infdis/jit647
   PubMed Web of Science ®Google Scholar
• Bagarazzi ML, Yan J, Morrow MP, Shen X, Parker RL, Lee JC, Giffear M, Pankhong P, Khan AS, Broderick KE, et al. Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med 2012; 4:155ra38; http://dx.doi.org/10.1126/scitranslmed.3004414
   Web of Science ®Google Scholar
• Kalams SA, Parker SD, Elizaga M, Metch B, Edupuganti S, Hural J, De Rosa S, Carter DK, Rybczyk K, Frank I, et al. Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. J Infect Dis 2013; 208:818-29; PMID:23840043; http://dx.doi.org/10.1093/infdis/jit236
   PubMed Web of Science ®Google Scholar
• Villarreal DO, Talbott KT, Choo DK, Shedlock DJ, Weiner DB. Synthetic DNA vaccine strategies against persistent viral infections. Exp Rev Vaccin 2013; 12:537-54; PMID:23659301; http://dx.doi.org/10.1586/erv.13.33
   PubMed Web of Science ®Google Scholar
• Li J, Valentin A, Ng S, Beach RK, Alicea C, Bergamaschi C, Felber BK, Pavlakis GN. Differential effects of IL-15 on the generation, maintenance and cytotoxic potential of adaptive cellular responses induced by DNA vaccination. Vaccine 2015; 33:1188-96; PMID:25559187; http://dx.doi.org/10.1016/j.vaccine.2014.12.046
   PubMed Web of Science ®Google Scholar
• Williman J, Young S, Buchan G, Slobbe L, Wilson M, Pang P, Austyn J, Preston S, Baird M. DNA fusion vaccines incorporating IL-23 or RANTES for use in immunization against influenza. Vaccine 2008; 26:5153-8; PMID:18456374; http://dx.doi.org/10.1016/j.vaccine.2008.03.084
   PubMed Web of Science ®Google Scholar
• Muthumani K, Flingai S, Wise M, Tingey C, Ugen KE, Weiner DB. Optimized and enhanced DNA plasmid vector based in vivo construction of a neutralizing anti-HIV-1 envelope glycoprotein Fab. Hum Vaccin Immunother 2013; 9:2253-62; PMID:24045230; http://dx.doi.org/10.4161/hv.26498
   PubMed Web of Science ®Google Scholar
• Oynebraten I, Hinkula J, Fredriksen AB, Bogen B. Increased generation of HIV-1 gp120-reactive CD8+ T cells by a DNA vaccine construct encoding the chemokine CCL3. PLoS One 2014; 9:e104814; PMID:25122197; http://dx.doi.org/10.1371/journal.pone.0104814
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, Hu Z, Gordon IJ, Yamshchikov G, Enama ME, Plummer S, Bailer R, Pearce MB, Tumpey TM, Koup RA, et al. Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans. Clin Vaccine Immunol 2012; 19:1792-7; PMID:22956656; http://dx.doi.org/10.1128/CVI.05663-11
   PubMed Web of Science ®Google Scholar
• Alam S, McNeel DG. DNA vaccines for the treatment of prostate cancer. Exp Rev Vaccin 2010; 9:731-45; PMID:20624047; http://dx.doi.org/10.1586/erv.10.64
   PubMed Web of Science ®Google Scholar
• Diaz CM, Chiappori A, Aurisicchio L, Bagchi A, Clark J, Dubey S, Fridman A, Fabregas JC, Marshall J, Scarselli E, et al. Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors. J Transl Med 2013; 11:62; PMID:23497415; http://dx.doi.org/10.1186/1479-5876-11-62
   PubMed Web of Science ®Google Scholar
• Tiriveedhi V, Tucker N, Herndon J, Li L, Sturmoski M, Ellis M, Ma C, Naughton M, Lockhart AC, Gao F, et al. Safety and preliminary evidence of biologic efficacy of a mammaglobin-a DNA vaccine in patients with stable metastatic breast cancer. Clin Cancer Res 2014; 20:5964-75; PMID:25451106; http://dx.doi.org/10.1158/1078-0432.CCR-14-0059
   PubMed Web of Science ®Google Scholar
• Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, Moreira ED, Jr., Ngan Y, Petersen LK, Lazcano-Ponce E, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015; 372:711-23; PMID:25693011; http://dx.doi.org/10.1056/NEJMoa1405044
   PubMed Web of Science ®Google Scholar